Cepheid Logo
Request Info
Location / Language

{{headingText}}

{{paragraphText}}

{{continueBtnLabel}}

{{initials}}
Main Menu
Location / Language

{{headingText}}

{{paragraphText}}

{{continueBtnLabel}}

Request Info
Request Info

Xpert® vanA/vanB

Order Now
Van A / Van B computer generated depiction.

Rapid VRE screening for active prevention, control, and outbreak management in around 48 minutes

The Need

an ill woman listens to a physician
  • Vancomycin Resistant Enterococci (VRE) are a growing public health threat and pose a risk to patient safety in healthcare facilities1
  • In healthcare settings, colonized patients and environmental contamination contribute to VRE spread1
  • High-risk patients colonized with VRE have 24 times the increased infection risk2
  • Infections caused by VRE are associated with high mortality3
  • VRE has an impact on patient length of stay, and in turn, hospitalization costs3
1 Levitus M. et al. Vancomycin-Resistant Enterococci. StatPearls July 17, 2023. https://www.ncbi.nlm.nih.gov/books/NBK513233/?report=reader#_NBK513233_pubdet. Accessed December 11, 2023
2 Alevizakos M, et al. Colonization with vancomycin-resistant enterococci and risk for bloodstream infection among patients with malignancy: a systematic review and meta-analysis. Open Forum Infect Dis. 2016 Dec;4(1):ofw246.
3 Eichel V,M, et al. Epidemiology and outcomes of vancomycin-resistant enterococcus infections: a systematic review and meta-analysis. Journal of Hospital Infection 141 (2023) 119e128

The Solution

a male and a female researchers scanning cepheid test cartridges
  • Rapid molecular detection of vanA/vanB genes associated with VRE colonization
  • Fast, active screening of high-risk patients to support infection control measures aimed at reducing transmission risk

The Impact

a smiling female doctor attends an elderly woman
  • The Xpert vanA/vanB test facilitates efficient infection control surveillance programs, published studies demonstrated:4
    – 93% reduction of turn around time from 70.5h with chromogenic agar culture to 4.6h
    – High negative predictive value supports identification of non-colonized patients
    – Associated with a reduction in the number of identified contact patients in published studies
    – One published economic analysis reported lower overall costs in a institutional setting when molecular screening was used compared with culture
  • Some studies reported fewer isolation days following the adoption of rapid molecular screening compared with culture.5
4 Birgand G, et al. Lucet JC. Rapid detection of glycopeptide-resistant enterococci: impact on decision-making and costs. Antimicrobial Resistant and Infection Control.
2013 Nov ; 2:30.
5 Holzknecht BJ, Hansen DS, Nielsen L, Kailow A, Jarløv JO. Screening for vancomycin-resistant enterococci with Xpert® vanA/vanB: diagnostic accuracy and impact on
infection control decision making. New Microbes New Infect. 2017 Jan 12;16:54-59

Connect To Better Outcomes

Request Info

Insights

Get More Insights